One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1

Pancreatic triglyceride lipase (PTL) and Niemann-Pick C1-like 1 (NPC1L1) have been identified as attractive therapeutic targets for obesity and hypercholesteremia, respectively. Obesity and hypercholesteremia usually co-exist, however no dual-inhibitors against PTL and NPC1L1 were reported for the treatment of obesity patients with hypercholesteremia so far. In this work, molecular hybridization-based one-step modification screening identified a potent dual-inhibitor against PTL and NPC1L1. Compound P1-11 has IC50 values of 2.1 mu M against PTL through covalent binding, as well as significantly reduces cholesterol absorption in a non-competitive inhibitory manner. Molecule docking and molecular dynamics studies revealed the reason of its activity to both PTL and NPC1L1. Moreover, the gene and protein expression levels of PTL and NPC1L1 were also determined respectively after the treatment of P1-11. Development of dual-inhibitors against PTL and NPC1L1 could provide novel treatment options for obesity patients with hypercholesteremia. The results of current research would great support the development of dual-inhibitors against PTL and NPC1L1. (C) 2021 Elsevier Masson SAS. All rights reserved.

Automated summary

A potent dual-inhibitor against pancreatic triglyceride lipase (PTL) and Niemann-Pick C1-like 1 (NPC1L1) has been identified through molecular hybridization-based one-step modification screening, named as P1-11. Compound P1-11 inhibits PTL via covalent binding with an IC50 value of 2.1 mu M, and significantly reduces cholesterol absorption in a non-competitive manner. This research supports the development of novel treatment options for obesity patients with hypercholesteremia by targeting PTL and NPC1L1 simultaneously.